%0 Journal Article
%T Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
%A Gazzah A
%A Gonzales DB
%A Levy A
%A Bahleda R
%A Ducreux M
%A Lacroix L
%A Soria JC
%J OncoTargets and Therapy
%D 2013
%I Dove Medical Press
%R http://dx.doi.org/10.2147/OTT.S38520
%X lecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion? Case report (555) Total Article Views Authors: Gazzah A, Gonzales DB, Levy A, Bahleda R, Ducreux M, Lacroix L, Soria JC Published Date February 2013 Volume 2013:6 Pages 95 - 97 DOI: http://dx.doi.org/10.2147/OTT.S38520 Received: 25 September 2012 Accepted: 25 October 2012 Published: 20 February 2013 Anas Gazzah,1 Daniel Barrios Gonzales,1 Antonin Levy,1 Rastislav Bahleda,1 Michel Ducreux,2 Ludovic Lacroix,3 Jean Charles Soria1 1SITEP (Service des Innovations Therapeutiques Pr¨Ścoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France; 2Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France; 3Department of Biology, Institut Gustave Roussy, Paris XI University, Villejuif, France Abstract: Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.
%K pancreatic cancer
%K PI3K
%K targeted therapy
%K molecular profiling
%U https://www.dovepress.com/molecular-guided-therapy-for-advanced-pancreatic-cancer-patients-with--peer-reviewed-article-OTT